These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 11702611)

  • 1. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Fritsch PO; Sidoroff A
    Am J Clin Dermatol; 2000; 1(6):349-60. PubMed ID: 11702611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review.
    Wong A; Malvestiti AA; Hafner Mde F
    Rev Assoc Med Bras (1992); 2016; 62(5):468-73. PubMed ID: 27656858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Hasegawa A; Abe R
    F1000Res; 2020; 9():. PubMed ID: 32595945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
    Halevy S
    Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Harr T; French LE
    Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Harr T; French LE
    Orphanet J Rare Dis; 2010 Dec; 5():39. PubMed ID: 21162721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
    Tan SK; Tay YK
    Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
    Chen CB; Wang CW; Chung WH
    Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.
    Abe R; Shimizu T; Shibaki A; Nakamura H; Watanabe H; Shimizu H
    Am J Pathol; 2003 May; 162(5):1515-20. PubMed ID: 12707034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
    Abe R
    J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
    Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
    French LE; Trent JT; Kerdel FA
    Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI
    Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience.
    Lalosevic J; Nikolic M; Gajic-Veljic M; Skiljevic D; Medenica L
    Int J Dermatol; 2015 Aug; 54(8):978-84. PubMed ID: 25385069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients.
    Saito N; Yoshioka N; Abe R; Qiao H; Fujita Y; Hoshina D; Suto A; Kase S; Kitaichi N; Ozaki M; Shimizu H
    J Allergy Clin Immunol; 2013 Feb; 131(2):434-41.e1-9. PubMed ID: 23111236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20 years study in a tertiary care hospital.
    Techasatian L; Panombualert S; Uppala R; Jetsrisuparb C
    World J Pediatr; 2017 Jun; 13(3):255-260. PubMed ID: 27650525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
    Saito Y; Nakamura R
    Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stevens-Johnson syndrome-toxic epidermal necrolysis overlap in a patient taking quetiapine and famotidine: a case report.
    Su CS; Kao CL
    J Med Case Rep; 2024 Jul; 18(1):344. PubMed ID: 39068499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome).
    Monteiro D; Egipto P; Barbosa J; Horta R; Amarante J; Silva P; Silva A
    Cutan Ocul Toxicol; 2017 Jun; 36(2):163-168. PubMed ID: 27487073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.